BioSpace News Archive

With billions invested in R&D over the past year to find vaccines and therapies for the novel coronavirus, a few select life sciences companies and academic institutions are working on the hypothesis that intranasal vaccines and therapies could be key to stopping COVID-19 in its tracks, and provide greater protection against transmission of COVID-19.

Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.

Amicus Therapeutics announced topline results from its Phase III PROPEL pivotal trial of AT-GAA (cipaglucosidase alfa and miglustat) for late-onset Pompe disease (LOPD). Although the results showed some positive data, it failed to hit the primary endpoint.

CohBar, Inc. is pioneering mitochondrial-based therapies with a candidate in a Phase Ia/Ib clinical trial as a potential treatment for nonalcoholic steatohepatitis (NASH) and obesity, where top-line results are expected later this year.

Josh Smiley’s termination from Eli Lilly for inappropriate communications with employees will cost more than a blow to his reputation.

After announcing topline data from two identical Phase III trials, Roche’s Genentech has doubled down on data and are now showing positive results from four studies for its newest blindness-fighting treatment.

The U.S. Food and Drug Administration (FDA) has several solid PDUFA dates in the middle of February. Here’s a look.

It was a busy week for clinical trial announcements and news. Here’s a look.

Findings from a pivotal trial published in The Lancet show Libtayo® (cemiplimab), a PD-1 inhibitor jointly developed and commercialized by Regeneron Pharmaceuticals and Sanofi, was superior to platinum-doublet chemotherapy for improving overall survival in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ≥50% PD-L1 expression in tumor cells.

Early results from University of Oxford’s RECOVERY trial showed Roche’s immunosuppressant Actemra reduced deaths and the need for mechanical ventilation in severe COVID patients.